Transcenta Holding Limited
HKEX:6628
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/IC
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Enterprise Value to Invested Capital (EV/IC) ratio compares a company`s total enterprise value to the capital invested in its business. It shows how efficiently the company`s market value reflects the funds used to generate returns.
Valuation Scenarios
If EV/IC returns to its 3-Year Average (0.6), the stock would be worth HK$1.27 (43% downside from current price).
| Scenario | EV/IC Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.1 | HK$2.23 |
0%
|
| 3-Year Average | 0.6 | HK$1.27 |
-43%
|
| 5-Year Average | 0.6 | HK$1.24 |
-44%
|
| Industry Average | 5.3 | HK$10.65 |
+377%
|
| Country Average | 1.9 | HK$3.89 |
+75%
|
Forward EV/IC
Today’s price vs future invested capital
Peer Comparison
| Market Cap | EV/IC | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
T
|
Transcenta Holding Limited
HKEX:6628
|
1B HKD | 1.1 | -4.3 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -1 260 263.1 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
365.2B USD | 4.5 | 87.3 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
178.1B USD | 3.6 | 22.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
163.4B USD | 3.7 | 19.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 966.7 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
107.7B USD | 7.3 | 27.2 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
74.1B USD | 5.6 | 16.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.3B EUR | 14.8 | 37.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.8 | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
60.2B AUD | 1.5 | 29.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.1 |
| Median | 1.9 |
| 70th Percentile | 3.4 |
| Max | 1 129 391.6 |
Other Multiples
Transcenta Holding Limited
Glance View
Transcenta Holding Ltd. is a clinical stage global biopharmaceutical company that integrates the capacities of discovery, research, development, manufacturing and business development. The company is headquartered in Suzhou, Anhui. The company went IPO on 2021-09-29. The firm's products include MSB2311, TST001, TST005, TST002, TST004, TST003, TST008, MSB0254 and TST006. The firm's all products are in the research and development (R&D) stage and have not been commercialized. The firm also provides contract developmentand manufacturing organization (CDMO) services, mainly including process development services, GMP / cGMP production services, cell line development services, sample testing services, formula optimization services and drug formation research.
